Prolongation of corneal allograft survival with liposome-encapsulated cyclosporine in the rat eye.
OBJECTIVE
To study the effects of different formulations of topical cyclosporine (Cyclosporin A [CsA]) on corneal allograft rejection in a rat model.


METHODS
Female Lewis rats received penetrating keratoplasties from female Wistar-Furth donors. A total of 78 allogeneic grafts were performed. An additional 15 syngeneic grafts (Lewis) were used as technical controls. Two CsA preparations with equivalent drug concentrations (2.1 mg/ml) were applied as drops: CsA encapsulated in large unilamellar liposomes (CsA-LIP) and CsA dissolved in olive oil (CsA-DR). Allogeneic grafts were randomly assigned to receive CsA-LIP or CsA-DR beginning on the day of surgery five times daily for 10 days. Animals without any treatment or receiving empty liposomes (EM-LIP) were used as treatment controls. Grafts were graded three times weekly and a rejection index was generated based on graft clarity, neovascularization, and vessel size.


RESULTS
All syngeneic grafts remained clear over the observation period of 60 days. Rejected allogeneic grafts without any treatment and those receiving EM-LIP or CsA-DR showed a mean survival time (+/- standard deviation) of 14 +/- 4, 14 +/- 5, and 14 +/- 4 days, respectively. There was no significant difference in mean survival time between the grafts without any treatment and those in CsA-DR or EM-LIP treatment groups. The mean survival time of rejected grafts in animals receiving CsA-LIP was prolonged to 20 +/- 4 days. There was a significant difference in the mean survival time between the CsA-LIP treatment group and groups receiving CsA-DR, EM-LIP, or no treatment (P < or = 0.05). The Kaplan-Meier survival curve of the CsA-LIP treatment group was significantly different from the other experimental groups. The graft survival rate in the CsA-LIP group was 77%, whereas the rate was 37% in the non-treated group, 45% in the CsA-DR group, and 36% in the EM-LIP group.


CONCLUSIONS
Encapsulation of CsA in liposomes might be a promising formulation for use in the prevention of corneal graft rejection.
Milani
J K
JK
Jules Stein Eye Institute, University of California, School of Medicine, Los Angeles.
Pleyer
U
U
Dukes
A
A
Chou
H J
HJ
Lutz
S
S
Rückert
D
D
Schmidt
K H
KH
Mondino
B J
BJ
D000818:Animals; D003315:Cornea / Q000187:drug effects* / Q000473:pathology / Q000601:surgery; D016572:Cyclosporine / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D004337:Drug Carriers; D005260:Female; D006085:Graft Survival / Q000187:drug effects*; D015948:Keratoplasty, Penetrating; D008081:Liposomes; D009883:Ophthalmic Solutions; D051381:Rats; D011917:Rats, Inbred Lew; D011920:Rats, Inbred WF; D014184:Transplantation, Homologous
D004337:Drug Carriers; D008081:Liposomes; D009883:Ophthalmic Solutions; D016572:Cyclosporine